Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.

Woo J, Choi DR, Storer BE, Yeung C, Halpern AB, Salit RB, Sorror ML, Woolston DW, Monahan T, Scott BL, Deeg HJ.

Haematologica. 2019 Jul 9. pii: haematol.2019.218677. doi: 10.3324/haematol.2019.218677. [Epub ahead of print]

2.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
3.

Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation.

Brusen RM, Cheng RK, Masri SC, Leedy D, Sorror ML.

Int J Cardiol. 2019 Oct 1;292:166-170. doi: 10.1016/j.ijcard.2019.05.032. Epub 2019 May 25.

PMID:
31171392
4.

Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification.

Sorror ML, Storer BE, Nyland J, Estey EH.

JAMA Oncol. 2019 Jul 1;5(7):1062-1064. doi: 10.1001/jamaoncol.2019.0902. No abstract available.

PMID:
31095246
5.

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, Lee SJ, Gopal AK, Dong JF, Garcia DA, Weiss NS, R Hingorani S.

Biol Blood Marrow Transplant. 2019 Mar;25(3):570-576. doi: 10.1016/j.bbmt.2018.10.015. Epub 2018 Oct 26.

PMID:
30940363
6.

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases.

Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML.

Blood. 2019 Feb 14;133(7):754-762. doi: 10.1182/blood-2018-09-876284. Epub 2018 Dec 13.

PMID:
30545834
7.

Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection.

Waghmare A, Xie H, Kuypers J, Sorror ML, Jerome KR, Englund JA, Boeckh M, Leisenring WM.

Biol Blood Marrow Transplant. 2019 May;25(5):1011-1021. doi: 10.1016/j.bbmt.2018.12.005. Epub 2018 Dec 8.

PMID:
30537551
8.

Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.

Elsawy M, Storer BE, Milano F, Sandmaier BM, Delaney C, Salit RB, Rashad AH, Woolfrey AE, Appelbaum FR, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2019 May;25(5):1045-1052. doi: 10.1016/j.bbmt.2018.11.030. Epub 2018 Nov 28.

PMID:
30500442
9.

Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality.

Sorror ML, Gooley TA, Maclean KH, Hubbard J, Marcondes MA, Torok-Storb BJ, Tewari M.

Bone Marrow Transplant. 2019 Jul;54(7):973-979. doi: 10.1038/s41409-018-0352-9. Epub 2018 Oct 2.

10.

Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes.

Wais V, Bunjes D, Kuchenbauer F, Sorror ML.

Expert Rev Hematol. 2018 Oct;11(10):805-816. doi: 10.1080/17474086.2018.1509703. Epub 2018 Aug 16. Review.

PMID:
30092693
11.

Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia-Reply.

Sorror ML, Storer BE, Estey EH.

JAMA Oncol. 2018 Jul 1;4(7):1014-1015. doi: 10.1001/jamaoncol.2018.0677. No abstract available.

PMID:
29799988
12.

Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients.

Ogimi C, Krantz EM, Golob JL, Waghmare A, Liu C, Leisenring WM, Woodard CR, Marquis S, Kuypers JM, Jerome KR, Pergam SA, Fredricks DN, Sorror ML, Englund JA, Boeckh M.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2293-2301. doi: 10.1016/j.bbmt.2018.05.016. Epub 2018 May 16.

PMID:
29777867
13.

Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Deeg HJ, Stevens EA, Salit RB, Ermoian RP, Fang M, Gyurkocza B, Sorror ML, Fatobene G, Baumgart J, Burroughs LM, Delaney C, Doney K, Egan DN, Flowers MED, Milano F, Radich JP, Scott BL, Sickle EJ, Wood BL, Yeung C, Storer BE.

Biol Blood Marrow Transplant. 2018 May;24(5):956-963. doi: 10.1016/j.bbmt.2017.12.785. Epub 2017 Dec 20.

14.

Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes.

Samuelson Bannow BT, Salit RB, Storer BE, Stevens EA, Wu D, Yeung C, Fang M, Petersdorf EW, Linenberger ML, Woo J, Sorror ML, Doney K, Sandmaier BM, Deeg HJ, Scott BL.

Biol Blood Marrow Transplant. 2018 Feb;24(2):386-392. doi: 10.1016/j.bbmt.2017.09.016. Epub 2017 Sep 29.

15.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

16.

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States.

Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A.

Blood. 2017 Aug 31;130(9):1156-1164. doi: 10.1182/blood-2017-03-772368. Epub 2017 Jul 3.

17.

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality.

Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens-Ayers T, Milano F, Delaney C, Sorror ML, Sandmaier BM, Nichols G, Zerr DM, Jerome KR, Schiffer JT, Boeckh M.

Blood. 2017 Apr 20;129(16):2316-2325. doi: 10.1182/blood-2016-10-748426. Epub 2017 Feb 16.

18.

Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.

Salit RB, Oliver DC, Delaney C, Sorror ML, Milano F.

Biol Blood Marrow Transplant. 2017 Apr;23(4):654-658. doi: 10.1016/j.bbmt.2017.01.084. Epub 2017 Feb 9.

19.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.

20.

Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.

Elsawy M, Sorror ML.

Bone Marrow Transplant. 2016 Oct;51(10):1283-1300. doi: 10.1038/bmt.2016.141. Epub 2016 Jun 6. Review.

PMID:
27272454
21.

Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia.

Cassaday RD, Alan Potts D Jr, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM.

Leuk Lymphoma. 2016 Sep;57(9):2109-18. doi: 10.3109/10428194.2016.1160080. Epub 2016 Mar 22.

22.

Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.

Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, Özkök S, Yi J, Sahoo F, Kimball LE, Jerome KR, Marks MA, Boeckh M.

Lancet Haematol. 2016 Mar;3(3):e119-27. doi: 10.1016/S2352-3026(15)00289-6. Epub 2016 Feb 20.

23.

Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG.

Cancer. 2015 Oct 15;121(20):3709-16. doi: 10.1002/cncr.29498. Epub 2015 Jul 24.

24.

Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.

Vaughn JE, Gooley T, Maziarz RT, Pulsipher MA, Bhatia S, Maloney DG, Sandmaier BM, Flowers ME, Storb R, Sorror ML.

Br J Haematol. 2015 Nov;171(3):411-6. doi: 10.1111/bjh.13591. Epub 2015 Jul 20.

25.

Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation.

ElSawy M, Storer BE, Pulsipher MA, Maziarz RT, Bhatia S, Maris MB, Syrjala KL, Martin PJ, Maloney DG, Sandmaier BM, Storb R, Sorror ML.

Br J Haematol. 2015 Aug;170(4):574-83. doi: 10.1111/bjh.13476. Epub 2015 May 5.

26.

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study.

Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. doi: 10.1016/j.bbmt.2015.04.004. Epub 2015 Apr 7.

27.

Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.

Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, Ciceri F, Oneto R, Bruno B, Martin PJ, Sandmaier BM, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1418-24. doi: 10.1016/j.bbmt.2015.04.002. Epub 2015 Apr 7.

28.

Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age.

Sorror ML.

Leuk Lymphoma. 2015;56(8):2235-6. doi: 10.3109/10428194.2015.1036260. Epub 2015 May 20. No abstract available.

29.

Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults.

Sorror ML, Estey E.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):21-33. doi: 10.1182/asheducation-2014.1.21. Epub 2014 Nov 18. Review.

PMID:
25696831
30.

Reevaluation of the pretransplant assessment of mortality score after allogeneic hematopoietic transplantation.

Au BK, Gooley TA, Armand P, Fang M, Madtes DK, Sorror ML, Boeckh MJ, Gibson CJ, Deeg HJ, Storb R, Appelbaum FR, Chien JW, Martin PJ.

Biol Blood Marrow Transplant. 2015 May;21(5):848-54. doi: 10.1016/j.bbmt.2015.01.011. Epub 2015 Jan 31.

31.

Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.

Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ, Rezvani AR, Storb RF, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2015 Feb;21(2):281-7. doi: 10.1016/j.bbmt.2014.10.024. Epub 2014 Nov 1.

32.

Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.

Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML.

Biol Blood Marrow Transplant. 2015 Jan;21(1):151-8. doi: 10.1016/j.bbmt.2014.10.006. Epub 2014 Oct 12.

33.

Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, Sorror ML, Deeg HJ, Storb R, Appelbaum FR.

Biol Blood Marrow Transplant. 2015 Feb;21(2):373-8. doi: 10.1016/j.bbmt.2014.09.022. Epub 2014 Sep 30.

34.

Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL, Estey E, Maloney DG, Appelbaum FR, Martin PJ, Storer BE.

J Clin Oncol. 2014 Oct 10;32(29):3249-56. doi: 10.1200/JCO.2013.53.8157. Epub 2014 Aug 25.

35.

Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.

Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, Burns LJ, Cahn JY, Duncan C, Hale GA, Halter J, Hayashi RJ, Hsu JW, Jacobsohn DA, Kamble RT, Kamani NR, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Myers KC, Ramanathan M, Saber W, Savani BN, Schouten HC, Socie G, Sorror ML, Steinberg A, Popat U, Wingard JR, Mattsson J, Majhail NS.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1777-84. doi: 10.1016/j.bbmt.2014.07.009. Epub 2014 Jul 17.

36.

Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation.

Walter RB, Gyurkocza B, Storer BE, Godwin CD, Pagel JM, Buckley SA, Sorror ML, Wood BL, Storb R, Appelbaum FR, Sandmaier BM.

Leukemia. 2015 Jan;29(1):137-44. doi: 10.1038/leu.2014.173. Epub 2014 Jun 3.

37.

Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allogeneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome.

Mawad R, Gooley TA, Rajendran JG, Fisher DR, Gopal AK, Shields AT, Sandmaier BM, Sorror ML, Deeg HJ, Storb R, Green DJ, Maloney DG, Appelbaum FR, Press OW, Pagel JM.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1363-8. doi: 10.1016/j.bbmt.2014.05.014. Epub 2014 May 20.

38.

"To combine or not to combine": optimizing risk assessment before allogeneic hematopoietic cell transplantation.

ElSawy M, Storer BE, Sorror ML.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1455-6. doi: 10.1016/j.bbmt.2014.05.005. Epub 2014 May 9. No abstract available.

39.

Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.

Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA, Maris MB, Davis C, Deeg HJ, Lee SJ, Maloney DG, Sandmaier BM, Appelbaum FR, Gooley TA.

Blood. 2014 Jul 10;124(2):287-95. doi: 10.1182/blood-2014-01-550566. Epub 2014 May 5.

40.

Clinical guide to fertility preservation in hematopoietic cell transplant recipients.

Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY, Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, Stratton P, Sorror ML, Warwick AB, Wingard JR, Loren AW, Majhail NS.

Bone Marrow Transplant. 2014 Apr;49(4):477-84. doi: 10.1038/bmt.2013.211. Epub 2014 Jan 13. Review.

41.

Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.

Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, Frangoul HA, Gajewski JL, Hale GA, Hsu JW, Kamble RT, Lazarus HM, Marks DI, Maziarz RT, Savani BN, Shah AJ, Shah N, Sorror ML, Wood WA, Majhail NS.

Biol Blood Marrow Transplant. 2014 Apr;20(4):587-92. doi: 10.1016/j.bbmt.2013.12.567. Epub 2014 Jan 2.

42.

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.

Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A, Drobyski WR, Freytes CO, Gale RP, Gasparetto CJ, Holmberg LA, Kamble RT, Krishnan AY, Kyle RA, Marks D, Nishihori T, Pasquini MC, Ramanathan M, Lonial S, Savani BN, Saber W, Sharma M, Sorror ML, Wirk BM, Hari PN.

Biol Blood Marrow Transplant. 2014 Mar;20(3):402-408.e1. doi: 10.1016/j.bbmt.2013.12.557. Epub 2013 Dec 14.

43.

Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia.

Sorror ML, Appelbaum FR.

Expert Rev Hematol. 2013 Oct;6(5):547-62. doi: 10.1586/17474086.2013.827418. Epub 2013 Oct 2. Review.

44.

Frequency of allogeneic hematopoietic cell transplantation among patients with high- or intermediate-risk acute myeloid leukemia in first complete remission.

Mawad R, Gooley TA, Sandhu V, Lionberger J, Scott B, Sandmaier BM, O'Donnell P, Becker PS, Petersdorf S, Dorcy KS, Hendrie P, Sorror ML, Walter RB, Deeg HJ, Appelbaum FR, Estey EH, Pagel JM.

J Clin Oncol. 2013 Nov 1;31(31):3883-8. doi: 10.1200/JCO.2013.50.2567. Epub 2013 Sep 23.

45.

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.

Jaklič A, Collins CJ, Mrhar A, Sorror ML, Sandmaier BM, Bemer MJ, Locatelli I, McCune JS.

Int J Clin Pharmacol Ther. 2013 Sep;51(9):711-7. doi: 10.5414/CP201884.

46.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM.

J Clin Oncol. 2013 Apr 20;31(12):1530-8. doi: 10.1200/JCO.2012.45.0247. Epub 2013 Mar 11.

47.

Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients.

Loren AW, Brazauskas R, Chow EJ, Gilleece M, Halter J, Jacobsohn DA, Joshi S, Pidala J, Quinn GP, Wang Z, Apperley JF, Burns LJ, Hale GA, Hayes-Lattin BM, Kamble R, Lazarus H, McCarthy PL, Reddy V, Warwick AB, Bolwell BJ, Duncan C, Socie G, Sorror ML, Wingard JR, Majhail NS.

Bone Marrow Transplant. 2013 Aug;48(8):1091-7. doi: 10.1038/bmt.2013.13. Epub 2013 Feb 18.

48.

Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects.

Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM.

Biol Blood Marrow Transplant. 2013 May;19(5):792-8. doi: 10.1016/j.bbmt.2013.02.006. Epub 2013 Feb 14.

49.

How I assess comorbidities before hematopoietic cell transplantation.

Sorror ML.

Blood. 2013 Apr 11;121(15):2854-63. doi: 10.1182/blood-2012-09-455063. Epub 2013 Jan 25.

50.

Second malignancies after autologous hematopoietic cell transplantation in children.

Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, Dilley KJ, Frangoul HA, Gross TG, Hale GA, Hayashi RJ, Hijiya N, Kamble RT, Lazarus HM, Marks DI, Reddy V, Savani BN, Warwick AB, Wingard JR, Wood WA, Sorror ML, Jacobsohn DA.

Bone Marrow Transplant. 2013 Mar;48(3):363-8. doi: 10.1038/bmt.2012.166. Epub 2012 Sep 10.

Supplemental Content

Loading ...
Support Center